Resources | NITAG RESOURCE CENTER

2024 ∙ ATAGI

ATAGI statement on the administration of seasonal influenza vaccines in 2024

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2023 ∙ Guo, Jianming Guo, Shuyan Dong, Siping

Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis

2023 ∙ Xiang, C. Zhang, J. Zhao, F. You, Y.

Emm type distribution of group A Streptococcus in China during 1990 and 2020: a systematic review and implications for vaccine coverage

2023 ∙ Yuan, D. Liu, S. Liu, Y. Ouyang, F. Ai, W. Shi, L. Liu, X. Qiu, T. Wang, B. Zhou, Y.

HPV Infection Profiles among People Living with HIV and HPV Vaccine Acceptance among Individuals with Different HIV Infection Statuses in China: A Systematic Meta-Analysis

2023 ∙ Liu, Y. Kuang, K.

Predictors of COVID-19 vaccination hesitancy in China: a meta-analysis

2023 ∙ Middleton, Bianca F. Danchin, Margie Fathima, Parveen Bines, Julie E. Macartney, Kristine Snelling, Thomas L.

Review of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006 - 2021

2023 ∙ ATAGI

ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines

2023 ∙ ATAGI

ATAGI Update on the COVID-19 Vaccination Program

2023 ∙ ATAGI

ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary vaccination of people aged 12 years or older